Terms: = Prostate cancer AND HLF, Q16534, 3131, ENSG00000108924
17 results:
1. Tensin 1 regulated by hepatic leukemia factor represses the progression of prostate cancer.
Zhou H; Wang F
Mutagenesis; 2023 Dec; 38(6):295-304. PubMed ID: 37712764
[TBL] [Abstract] [Full Text] [Related]
2. Retrospective analysis of the uptake of active surveillance for low-risk prostate cancer in Zurich, Switzerland.
Poyet C; Scherer TP; Kunz M; Wanner M; Korol D; Rizzi G; Kaufmann B; Rohrmann S; Hermanns T
Swiss Med Wkly; 2023 Jul; 153():40103. PubMed ID: 37499067
[TBL] [Abstract] [Full Text] [Related]
3. Glycaemic index, glycaemic load and cancer risk: results from the prospective NutriNet-Santé cohort.
Debras C; Chazelas E; Srour B; Julia C; Kesse-Guyot E; Zelek L; Agaësse C; Druesne-Pecollo N; Andreeva VA; Galan P; Hercberg S; Latino-Martel P; Deschasaux-Tanguy M; Touvier M
Int J Epidemiol; 2022 Feb; 51(1):250-264. PubMed ID: 34491326
[TBL] [Abstract] [Full Text] [Related]
4. Antitumor activity of a hydrogel loaded with lipophilic bismuth nanoparticles on cervical, prostate, and colon human cancer cells.
Cabral-Romero C; Solís-Soto JM; Sánchez-Pérez Y; Pineda-Aguilar N; Meester I; Pérez-Carrillo E; Nakagoshi-Cepeda SE; Sánchez-Nájera RI; Nakagoshi-Cepeda MAA; Hernandez-Delgadillo R; Chellam S; García-Cuéllar CM
Anticancer Drugs; 2020 Mar; 31(3):251-259. PubMed ID: 31764012
[TBL] [Abstract] [Full Text] [Related]
5. Internal Fusion: exact correlation of transrectal ultrasound images of the prostate by detailed landmarks over time for targeted biopsies or follow-up.
Xie Y; Tokas T; Grabski B; Loch T
World J Urol; 2018 May; 36(5):693-698. PubMed ID: 29282497
[TBL] [Abstract] [Full Text] [Related]
6. Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET/CT in the general population.
Naganawa S; Yoshikawa T; Yasaka K; Maeda E; Hayashi N; Abe O
Medicine (Baltimore); 2017 Nov; 96(46):e8832. PubMed ID: 29145346
[TBL] [Abstract] [Full Text] [Related]
7. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma.
Sawahara H; Shiraha H; Uchida D; Kato H; Kato R; Oyama A; Nagahara T; Iwamuro M; Horiguchi S; Tsutsumi K; Mandai M; Mimura T; Wada N; Takeuchi Y; Kuwaki K; Onishi H; Nakamura S; Watanabe M; Sakaguchi M; Takaki A; Nouso K; Yagi T; Nasu Y; Kumon H; Okada H
J Gastroenterol Hepatol; 2017 Oct; 32(10):1769-1777. PubMed ID: 28168749
[TBL] [Abstract] [Full Text] [Related]
8. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
[TBL] [Abstract] [Full Text] [Related]
9. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of qualitative and quantitative approach to prostate MR spectroscopy in peripheral zone cancer detection.
Klijn S; De Visschere PJ; De Meerleer GO; Villeirs GM
Eur J Radiol; 2012 Mar; 81(3):411-6. PubMed ID: 21215541
[TBL] [Abstract] [Full Text] [Related]
11. Utilisation of radiotherapy in rural and urban areas in British Columbia compared with evidence-based estimates of radiotherapy needs for patients with breast, prostate and lung cancer.
Tyldesley S; McGahan C
Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):526-32. PubMed ID: 20594811
[TBL] [Abstract] [Full Text] [Related]
12. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
Scheble VJ; Braun M; Beroukhim R; Mermel CH; Ruiz C; Wilbertz T; Stiedl AC; Petersen K; Reischl M; Kuefer R; Schilling D; Fend F; Kristiansen G; Meyerson M; Rubin MA; Bubendorf L; Perner S
Mod Pathol; 2010 Aug; 23(8):1061-7. PubMed ID: 20473283
[TBL] [Abstract] [Full Text] [Related]
13. Noninvasive discrimination of human normal cells and malignant tumor cells by phase-shifting laser microscopy.
Tokumitsu A; Wakitani S; Takagi M
J Biosci Bioeng; 2010 May; 109(5):499-503. PubMed ID: 20347774
[TBL] [Abstract] [Full Text] [Related]
14. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
[TBL] [Abstract] [Full Text] [Related]
15. Loss of annexin II heavy and light chains in prostate cancer and its precursors.
Chetcuti A; Margan SH; Russell P; Mann S; Millar DS; Clark SJ; Rogers J; Handelsman DJ; Dong Q
Cancer Res; 2001 Sep; 61(17):6331-4. PubMed ID: 11522620
[TBL] [Abstract] [Full Text] [Related]
16. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer.
Kelley MR; Cheng L; Foster R; Tritt R; Jiang J; Broshears J; Koch M
Clin Cancer Res; 2001 Apr; 7(4):824-30. PubMed ID: 11309329
[TBL] [Abstract] [Full Text] [Related]
17. Going APE over ref-1.
Evans AR; Limp-Foster M; Kelley MR
Mutat Res; 2000 Oct; 461(2):83-108. PubMed ID: 11018583
[TBL] [Abstract] [Full Text] [Related]
